申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2000037470A1
公开(公告)日:2000-06-29
This invention concerns the compounds of formula (I) a prodrug, a N-oxide, an addition salt, a quaternary amine or a stereochemically isomeric form thereof wherein R1 is hydrogen, C¿1-6?alkyl, halo, formyl, carboxyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyl, N(R?3R4¿)C(=O)-, N(R3R4)C(=O)N(R5)-, ethenyl substituted with carboxyl or C¿1-6?alkyloxycarbonyl, or C1-6alkyl substituted with hydroxy, carboxyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, N(R?3R4¿)C(=O)-, C¿1-6?alkylC(=O)N(R?5¿)-, C¿1-6?alkylS(=O)2N(R?5¿)- or N(R3R4)C(=O)N(R5)- wherein each R3 and each R4 independently are hydrogen or C¿1-4?alkyl, and R?5¿ is hydrogen or hydroxy; R2 is hydrogen, C¿1-6?alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, N(R?3R4¿)C(=O)-, aryl or halo; n is 1 or 2; -A-B- represents a bivalent radical of formula -Y-CH=CH-, -CH=CH-Y-, or -CH=CH-CH=CH-, wherein each hydrogen atom may independently be replaced by R6 wherein R6 is C¿1-6?alkyl, halo, hydroxy, C1-6alkyloxy, ethenyl substituted with carboxyl or C1-6alkyloxycarbonyl, hydroxyC1-6alkyl, formyl, carboxyl or hydroxycarbonylC1-6alkyl, and each Y independently is a bivalent radical of formula -O-, -S- or -NR?7¿-, wherein R7 is hydrogen, C¿1-6?alkyl or C1-6alkylcarbonyl; Z is a bivalent radical of formula -(CH2)p-, -CH=CH-, -CH2-CHOH-, -CH2-O-, -CH2-C(=O), or -CH2-C(=NOH)-, provided that the bivalent radicals are connected to the nitrogen of the imidazole ring via their -CH2- moiety; and wherein p is 1, 2, 3 or 4; L is hydrogen; C1-6alkyl; C2-6alkenyl; C1-6alkylcarbonyl; C1-6alkyloxycarbonyl; C1-6alkyl substituted with hydroxy, carboxyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, aryl, aryloxy, cyano or R?8¿HN- wherein R8 is hydrogen, C¿1-6?alkyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyl; or L represents a radical of formula -Alk-Y-Het?1¿, -Alk-NH-CO-Het2 or -Alk-Het3 wherein Alk represents C¿1-4?alkanediyl; Y represents O, S or NH; Het?1, Het2¿ and Het3 each represent an optionally substituted heterocycle; for use as a medicine.
本发明涉及具有式(I)的化合物,它是一种前药、N-氧化物、加成盐、季铵盐或立体化学异构体,其中R1是氢、C1-6烷基、卤素、甲酰基、羧基、C1-6烷氧羰基、C1-6烷基羰基、N(R3R4)C(=O)-、N(R3R4)C(=O)N(R5)-、乙烯基取代的羧基或C1-6烷氧羰基,或C1-6烷基取代的羟基、羧基、C1-6烷氧基、C1-6烷氧羰基、N(R3R4)C(=O)-、C1-6烷基C(=O)N(R5)-、C1-6烷基S(=O)2N(R5)-或N(R3R4)C(=O)N(R5)-,其中每个R3和每个R4独立地是氢或C1-4烷基,而R5是氢或羟基;R2是氢、C1-6烷基、羟基C1-6烷基、C1-6烷氧基C1-6烷基、N(R3R4)C(=O)-、芳基或卤素;n为1或2;-A-B-表示式-Y-CH=CH-,-CH=CH-Y-或-CH=CH-CH=CH-的二价基团,其中每个氢原子可以独立地被R6取代,其中R6是C1-6烷基、卤素、羟基、C1-6烷氧基、乙烯基取代的羧基或C1-6烷氧羰基、羟基C1-6烷基、甲酰基、羧基或羟基羧基C1-6烷基,每个Y独立地是-O-、-S-或-NR7-的式子,其中R7是氢、C1-6烷基或C1-6烷基羰基;Z是式-(CH2)p-、-CH=CH-、-CH2-CHOH-、-CH2-O-、-CH2-C(=O)或-CH2-C(=NOH)-的二价基团,前提是二价基团通过它们的-CH2-部分连接到咪唑环的氮上;其中p为1、2、3或4;L是氢、C1-6烷基、C2-6烯基、C1-6烷基羰基、C1-6烷氧羰基、取代羟基、羧基、C1-6烷氧基、C1-6烷氧羰基、芳基、芳氧基、氰基或R8HN-的C1-6烷基,其中R8是氢、C1-6烷基、C1-6烷氧羰基、C1-6烷基羰基;或L表示式-Alk-Y-Het1,-Alk-NH-CO-Het2或-Alk-Het3,其中Alk表示C1-4烷二基;Y表示O、S或NH;Het1、Het2和Het3各自表示一个可选择取代的杂环;用作药物。